These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 34795410)

  • 1. Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models.
    Nakayama A; Nagashima T; Nishizono Y; Kuramoto K; Mori K; Homboh K; Yuri M; Shimazaki M
    Br J Cancer; 2022 Mar; 126(5):744-753. PubMed ID: 34795410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
    Canon J; Rex K; Saiki AY; Mohr C; Cooke K; Bagal D; Gaida K; Holt T; Knutson CG; Koppada N; Lanman BA; Werner J; Rapaport AS; San Miguel T; Ortiz R; Osgood T; Sun JR; Zhu X; McCarter JD; Volak LP; Houk BE; Fakih MG; O'Neil BH; Price TJ; Falchook GS; Desai J; Kuo J; Govindan R; Hong DS; Ouyang W; Henary H; Arvedson T; Cee VJ; Lipford JR
    Nature; 2019 Nov; 575(7781):217-223. PubMed ID: 31666701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination.
    Rosell R; Jantus-Lewintre E; Cao P; Cai X; Xing B; Ito M; Gomez-Vazquez JL; Marco-Jordán M; Calabuig-Fariñas S; Cardona AF; Codony-Servat J; Gonzalez J; València-Clua K; Aguilar A; Pedraz-Valdunciel C; Dantes Z; Jain A; Chandan S; Molina-Vila MA; Arrieta O; Ferrero M; Camps C; González-Cao M
    Cell Commun Signal; 2024 Jun; 22(1):324. PubMed ID: 38867255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virtual clinical trial simulations for a novel KRAS
    Sayama H; Marcantonio D; Nagashima T; Shimazaki M; Minematsu T; Apgar JF; Burke JM; Wille L; Nagasaka Y; Kirouac DC
    CPT Pharmacometrics Syst Pharmacol; 2021 Aug; 10(8):864-877. PubMed ID: 34043291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional dissection of the KRAS G12C mutation by comparison among multiple oncogenic driver mutations in a lung cancer cell line model.
    Kobayashi K; Terai H; Yasuda H; Hamamoto J; Hayashi Y; Takeuchi O; Mitsuishi Y; Masuzawa K; Manabe T; Ikemura S; Kawada I; Suzuki Y; Soejima K; Fukunaga K
    Biochem Biophys Res Commun; 2021 Jan; 534():1-7. PubMed ID: 33302159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diverse alterations associated with resistance to KRAS(G12C) inhibition.
    Zhao Y; Murciano-Goroff YR; Xue JY; Ang A; Lucas J; Mai TT; Da Cruz Paula AF; Saiki AY; Mohn D; Achanta P; Sisk AE; Arora KS; Roy RS; Kim D; Li C; Lim LP; Li M; Bahr A; Loomis BR; de Stanchina E; Reis-Filho JS; Weigelt B; Berger M; Riely G; Arbour KC; Lipford JR; Li BT; Lito P
    Nature; 2021 Nov; 599(7886):679-683. PubMed ID: 34759319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-targeting SOS1 enhances the antitumor effects of KRAS
    Thatikonda V; Lyu H; Jurado S; Kostyrko K; Bristow CA; Albrecht C; Alpar D; Arnhof H; Bergner O; Bosch K; Feng N; Gao S; Gerlach D; Gmachl M; Hinkel M; Lieb S; Jeschko A; Machado AA; Madensky T; Marszalek ED; Mahendra M; Melo-Zainzinger G; Molkentine JM; Jaeger PA; Peng DH; Schenk RL; Sorokin A; Strauss S; Trapani F; Kopetz S; Vellano CP; Petronczki M; Kraut N; Heffernan TP; Marszalek JR; Pearson M; Waizenegger IC; Hofmann MH
    Nat Cancer; 2024 Sep; 5(9):1352-1370. PubMed ID: 39103541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS Inhibitor Resistance in
    Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
    Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCL-X
    Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
    J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade.
    Nokin MJ; Mira A; Patrucco E; Ricciuti B; Cousin S; Soubeyran I; San José S; Peirone S; Caizzi L; Vietti Michelina S; Bourdon A; Wang X; Alvarez-Villanueva D; Martínez-Iniesta M; Vidal A; Rodrigues T; García-Macías C; Awad MM; Nadal E; Villanueva A; Italiano A; Cereda M; Santamaría D; Ambrogio C
    Nat Commun; 2024 Aug; 15(1):7554. PubMed ID: 39215000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR Blockade Reverts Resistance to KRAS
    Amodio V; Yaeger R; Arcella P; Cancelliere C; Lamba S; Lorenzato A; Arena S; Montone M; Mussolin B; Bian Y; Whaley A; Pinnelli M; Murciano-Goroff YR; Vakiani E; Valeri N; Liao WL; Bhalkikar A; Thyparambil S; Zhao HY; de Stanchina E; Marsoni S; Siena S; Bertotti A; Trusolino L; Li BT; Rosen N; Di Nicolantonio F; Bardelli A; Misale S
    Cancer Discov; 2020 Aug; 10(8):1129-1139. PubMed ID: 32430388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.
    Adachi Y; Ito K; Hayashi Y; Kimura R; Tan TZ; Yamaguchi R; Ebi H
    Clin Cancer Res; 2020 Nov; 26(22):5962-5973. PubMed ID: 32900796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRAS
    Ryan MB; Fece de la Cruz F; Phat S; Myers DT; Wong E; Shahzade HA; Hong CB; Corcoran RB
    Clin Cancer Res; 2020 Apr; 26(7):1633-1643. PubMed ID: 31776128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D-1553: A novel KRAS
    Shi Z; Weng J; Niu H; Yang H; Liu R; Weng Y; Zhu Q; Zhang Y; Tao L; Wang Z; Huh SJ; Jiang Y; Mei H; Dai X; Zhang L; Wang Y
    Cancer Sci; 2023 Jul; 114(7):2951-2960. PubMed ID: 37158138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 mediates clinical resistance to the KRAS
    Ho CSL; Tüns AI; Schildhaus HU; Wiesweg M; Grüner BM; Hegedus B; Schuler M; Schramm A; Oeck S
    Eur J Cancer; 2021 Dec; 159():16-23. PubMed ID: 34715459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Acquired Resistance to KRAS
    Tanaka N; Lin JJ; Li C; Ryan MB; Zhang J; Kiedrowski LA; Michel AG; Syed MU; Fella KA; Sakhi M; Baiev I; Juric D; Gainor JF; Klempner SJ; Lennerz JK; Siravegna G; Bar-Peled L; Hata AN; Heist RS; Corcoran RB
    Cancer Discov; 2021 Aug; 11(8):1913-1922. PubMed ID: 33824136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonclinical Safety Profile of Sotorasib, a KRAS
    Ishida K; Werner JA; Davies R; Fan F; Thomas B; Wahlstrom J; Lipford JR; Monticello T
    Int J Toxicol; 2021 Oct; 40(5):427-441. PubMed ID: 34137282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
    Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
    Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers.
    Khan HY; Nagasaka M; Li Y; Aboukameel A; Uddin MH; Sexton R; Bannoura S; Mzannar Y; Al-Hallak MN; Kim S; Beydoun R; Landesman Y; Mamdani H; Uprety D; Philip PA; Mohammad RM; Shields AF; Azmi AS
    Cancer Res Commun; 2022 May; 2(5):342-352. PubMed ID: 35573474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.
    Holderfield M; Lee BJ; Jiang J; Tomlinson A; Seamon KJ; Mira A; Patrucco E; Goodhart G; Dilly J; Gindin Y; Dinglasan N; Wang Y; Lai LP; Cai S; Jiang L; Nasholm N; Shifrin N; Blaj C; Shah H; Evans JW; Montazer N; Lai O; Shi J; Ahler E; Quintana E; Chang S; Salvador A; Marquez A; Cregg J; Liu Y; Milin A; Chen A; Ziv TB; Parsons D; Knox JE; Klomp JE; Roth J; Rees M; Ronan M; Cuevas-Navarro A; Hu F; Lito P; Santamaria D; Aguirre AJ; Waters AM; Der CJ; Ambrogio C; Wang Z; Gill AL; Koltun ES; Smith JAM; Wildes D; Singh M
    Nature; 2024 May; 629(8013):919-926. PubMed ID: 38589574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.